These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35941997)

  • 1. The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC.
    Kanemura H; Hayashi H; Tomida S; Tanizaki J; Suzuki S; Kawanaka Y; Tsuya A; Fukuda Y; Kaneda H; Kudo K; Takahama T; Imai R; Haratani K; Chiba Y; Otani T; Ito A; Sakai K; Nishio K; Nakagawa K
    JTO Clin Res Rep; 2022 Aug; 3(8):100373. PubMed ID: 35941997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
    Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF
    PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
    Zhang S; Li S; Cheng Y
    Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.
    Shirasawa M; Yoshida T; Shiraishi K; Takigami A; Takayanagi D; Imabayashi T; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yotsukura M; Yoshida Y; Nakagawa K; Tsuchida T; Hamamoto R; Yamamoto N; Motoi N; Kohno T; Watanabe SI; Ohe Y
    Lung Cancer; 2023 May; 179():107183. PubMed ID: 37037178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic immune index predicts tumor-infiltrating lymphocyte intensity and immunotherapy response in small cell lung cancer.
    Deng C; Liao J; Fu Z; Fu F; Li D; Li Y; Wang J; Chen H; Zhang Y
    Transl Lung Cancer Res; 2024 Feb; 13(2):292-306. PubMed ID: 38496688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
    Shirasawa M; Yoshida T; Shiraishi K; Goto N; Yagishita S; Imabayashi T; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yotsukura M; Yoshida Y; Nakagawa K; Naoki K; Tsuchida T; Hamamoto R; Yamamoto N; Motoi N; Kohno T; Watanabe SI; Ohe Y
    Br J Cancer; 2023 Dec; 129(12):2003-2013. PubMed ID: 37731022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
    Zhang L; Han X; Shi Y
    JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
    Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH
    J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma.
    Kanemura H; Yokoyama T; Nakajima R; Nakamura A; Kuroda H; Kitamura Y; Shoda H; Mamesaya N; Miyata Y; Okamoto T; Okishio K; Oki M; Sakairi Y; Chen-Yoshikawa TF; Aoki T; Ohira T; Matsumoto I; Ueno K; Miyazaki T; Matsuguma H; Yokouchi H; Otani T; Ito A; Sakai K; Chiba Y; Nishio K; Yamamoto N; Okamoto I; Nakagawa K; Takeda M
    JTO Clin Res Rep; 2024 Apr; 5(4):100658. PubMed ID: 38651033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses.
    Gristina V; Galvano A; Castellana L; Insalaco L; Cusenza S; Graceffa G; Iacono F; Barraco N; Castiglia M; Perez A; Rizzo S; Russo A; Bazan V
    Ther Adv Med Oncol; 2021; 13():17588359211018018. PubMed ID: 34646363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversing resistance to immune checkpoint inhibitor by adding recombinant human adenovirus type 5 in a patient with small cell lung cancer with promoted immune infiltration: a case report.
    Zhao Q; Tong J; Liu X; Li S; Chen D; Miao L
    J Cancer Res Clin Oncol; 2022 May; 148(5):1269-1273. PubMed ID: 35212817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC.
    Thomas PL; Groves SM; Zhang YK; Li J; Gonzalez-Ericsson P; Sivagnanam S; Betts CB; Chen HC; Liu Q; Lowe C; Chen H; Boyd KL; Kopparapu PR; Yan Y; Coussens LM; Quaranta V; Tyson DR; Iams W; Lovly CM
    J Thorac Oncol; 2021 Jul; 16(7):1211-1223. PubMed ID: 33839362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study.
    Ishida M; Morimoto K; Yamada T; Takeda T; Shiotsu S; Date K; Harada T; Tamiya N; Chihara Y; Takemura Y; Yamada T; Kanda H; Iwasaku M; Tokuda S; Kim YH; Takayama K
    JTO Clin Res Rep; 2023 Apr; 4(4):100493. PubMed ID: 37025120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line immune-checkpoint inhibitor plus chemotherapy
    Landre T; Chouahnia K; Des Guetz G; Duchemann B; Assié JB; Chouaïd C
    Ther Adv Med Oncol; 2020; 12():1758835920977137. PubMed ID: 33343721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
    Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
    ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer.
    Chen T; Wang M; Chen Y; Cao Y; Liu Y
    Cell Biosci; 2024 Sep; 14(1):117. PubMed ID: 39267195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials.
    Facchinetti F; Di Maio M; Tiseo M
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32947924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study.
    Thomas A; Vilimas R; Trindade C; Erwin-Cohen R; Roper N; Xi L; Krishnasamy V; Levy E; Mammen A; Nichols S; Chen Y; Velcheti V; Yin F; Szabo E; Pommier Y; Steinberg SM; Trepel JB; Raffeld M; Young HA; Khan J; Hewitt S; Lee JM
    J Thorac Oncol; 2019 Aug; 14(8):1447-1457. PubMed ID: 31063862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.